Judith Fraussen

Judith Fraussen

Auto-generated profile, based on publicly available information

Judith Fraussen

Department of Immunology and Infection, Biomedical Research Institute, UHasselt - Hasselt University, Hasselt, Belgium

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NCNele Claes
Nele Claes
JFJudith Fraussen
Judith Fraussen
MVMarjan Vanheusden
Marjan Vanheusden
NHNiels Hellings
Niels Hellings
PSPiet Stinissen
Piet Stinissen
VSVeerle Somers
Veerle Somers
Immune aging occurs in the elderly and in autoimmune diseases. Recently, IgD−CD27− (double negative, DN) and CD21−CD11c+ (CD21low) B cells were described as age-associated B cells with proinflammatory characteristics. This study investigated the prevalence and functional characteristics of DN and CD21low B cells in multiple sclerosis (MS) patients. Using flow cytometry, we demonstrated a higher proportion of MS patients younger than 60 y with peripheral expansions of DN (8/41) and CD21low (9/41) B cells compared with age-matched healthy donors (1/33 and 2/33, respectively), which indicates an increase in age-associated B cells in MS patients. The majority of DN B cells had an IgG+ memory phenotype, whereas CD21low B cells consisted of a mixed population of CD27− naive, CD27+ memory, IgG+, and IgM+ cells. DN B cells showed similar (MS patients) or increased (healthy donors) MHC-II expression as class-switched memory B cells and intermediate costimulatory molecule expression between naive and class-switched memory B cells, indicating their potential to induce (proinflammatory) T cell responses. Further, DN B cells produced proinflammatory and cytotoxic cytokines following ex vivo stimulation. Increased frequencies of DN and CD21low B cells were found in the cerebrospinal fluid of MS patients compared with paired peripheral blood. In conclusion, a proportion of MS patients showed increased peripheral expansions of age-associated B cells. DN and CD21low B cell frequencies were further increased in MS cerebrospinal fluid. These cells could contribute to inflammation by induction of T cell responses and the production of proinflammatory cytokines.

15 November 2007 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MTMarielle Thewissen
Marielle Thewissen
VSVeerle Somers
Veerle Somers
NHNiels Hellings
Niels Hellings
JFJudith Fraussen
Judith Fraussen
JDJan Damoiseaux
Jan Damoiseaux
PSPiet Stinissen
Piet Stinissen
To determine the role of expanded CD4+CD28null T cells in multiple sclerosis and rheumatoid arthritis pathology, these cells were phenotypically characterized and their Ag reactivity was studied. FACS analysis confirmed that CD4+CD28null T cells are terminally differentiated effector memory cells. In addition, they express phenotypic markers that indicate their capacity to infiltrate into tissues and cause tissue damage. Whereas no reactivity to the candidate autoantigens myelin basic protein and collagen type II was observed within the CD4+CD28null T cell subset, CMV reactivity was prominent in four of four HC, four of four rheumatoid arthritis patients, and three of four multiple sclerosis patients. The level of the CMV-induced proliferative response was found to be related to the clonal diversity of the response. Interestingly, our results illustrate that CD4+CD28null T cells are not susceptible to the suppressive actions of CD4+CD25+ regulatory T cells. In conclusion, this study provides several indications for a role of CD4+CD28null T cells in autoimmune pathology. CD4+CD28null T cells display pathogenic features, fill up immunological space, and are less susceptible to regulatory mechanisms. However, based on their low reactivity to the autoantigens tested in this study, CD4+CD28null T cells most likely do not play a direct autoaggressive role in autoimmune disease.

1 December 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
GDGwendoline Montes Diaz
Gwendoline Montes Diaz
RHRaymond Hupperts
Raymond Hupperts
JFJudith Fraussen
Judith Fraussen
VSVeerle Somers
Veerle Somers

9 March 2023 in Immunology Letters
Verified
Journal Article
Closed access
LBLien Beckers
Lien Beckers
VSVeerle Somers
Veerle Somers
JFJudith Fraussen
Judith Fraussen

31 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NCNele Claes
Nele Claes
TDTessa Dhaeze
Tessa Dhaeze
JFJudith Fraussen
Judith Fraussen
BBBieke Broux
Bieke Broux
BWBart Van Wijmeersch
Bart Van Wijmeersch
VSVeerle Somers
Veerle Somers
The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p<0.001), both implicated in MS pathogenesis, while the proportion of naive B cells was increased during fingolimod treatment in the peripheral blood (PB) of MS patients (p<0.05). The remaining T cell population, in contrast, showed elevated proportions of memory conventional and regulatory T cells (p<0.01) and declined proportions of naive conventional and regulatory cells (p<0.05). These naive T cell subtypes are main drivers of MS pathogenesis. B cell expression of CD80 and CD86 and programmed death (PD) -1 expression on circulating follicular helper T cells was increased during fingolimod follow-up (p<0.05) pointing to a potentially compensatory mechanism of the remaining circulating lymphocyte subtypes that could provide additional help during normal immune responses. MS patients treated with fingolimod showed a change in PB lymphocyte subtype proportions and expression of functional molecules on T and B cells, suggesting an association with the therapeutic efficacy of fingolimod.

1 November 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
JFJudith Fraussen
Judith Fraussen
NCNele Claes
Nele Claes
LBLaura de Bock
Laura de Bock
VSVeerle Somers
Veerle Somers